EOElizabeth C. Oelsner

Elizabeth C. Oelsner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Elizabeth C. Oelsner has a total of 937 co-authors. Here are the top co-authors by number of shared publications:

  • R. Graham Barr

    Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, USA

    12 shared publications
  • Ravi Kalhan

    Division of Pulmonary/Critical Care, Northwestern University, Chicago, Illinois, USA

    10 shared publications
  • Stephanie J. London

    Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, USA

    9 shared publications
  • Victor E. Ortega

    Division of Respiratory Medicine, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona

    9 shared publications
  • David Couper

    Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

    8 shared publications
  • Eric A. Hoffman

    Department of Radiology, University of Iowa, Iowa City, Iowa

    8 shared publications

Latest Publications

  • Associations of Depressive Symptoms With COVID-19 Hospitalization or Death: The C4R Study

    by Elizabeth C. Oelsner, Yifei Sun, Pallavi P. Balte, Norrina B. Allen, Howard Andrews, April P. Carson, Yuni Choi, Shelley A. Cole, Talea Cornelius, David Couper, et al.

    Objective: To investigate the relationship between depressive symptoms and risk for COVID-19 hospitalization and death in a US general population-based sample. Methods: We studied participants enrolled in observational NIH-funded cohorts from 1971 to 2010 with ongoing follow-up through 2023. Prepandemic Centers for Epidemiologic Studies Depression (CES-D) 10-item scale scores ≥10 defined elevated depressive symptoms. Questionnaires, medical records, and death certificates classified incidents of COVID-19 as severe (hospitalized/fatal) or nonsevere from April 2020 through February 2023. Results: Of 33,565 participants, 633 (1.9%) had incident severe COVID-19 over a mean (SD) follow-up of 453 (207) days. Elevated prepandemic depressive symptoms were present in 4922 (16.3%) of participants. Elevated prepandemic depressive symptoms increased the hazard of severe COVID-19 in fully adjusted (aHR=1.27; 95% CI=1.03-1.57) models. In sex-stratified models ( p -interaction=.03), elevated depressive symptoms increased the hazard in women (aHR=1.49; 95% CI=1.17-1.90) but not in men (aHR=0.96; 95% CI=0.67-1.39). Conclusions: Prepandemic depressive symptoms were associated with increased risk of severe COVID-19 among women in a large US general population-based study of adults, and associations in men were neither confirmed nor ruled out. These results support current CDC recommendations that depression be considered an underlying medical condition associated with a higher risk for severe COVID-19 and suggest that increased clinical focus on risk mitigation for COVID-19 and other acute respiratory infections among patients with depressive symptoms is warranted.

  • Open Access

    Associations of Pre-Pandemic CKD With Acute and Post-Acute COVID-19: The C4R Study

    by Yuni Choi, David R. Jacobs, Holly J. Kramer, Josef Coresh, Mary Cushman, Alexander P. Reiner, Ryan T. Demmer, Russell P. Tracy, Yifei Sun, Pallavi P. Balte, et al.


  • Open Access

    Life's Essential 8 and Risk of Severe COVID‐19 Among Adults Without Clinical Cardiovascular Disease: The C4R Study

    by Timothy B. Plante, Yifei Sun, Pallavi P. Balte, Donald Lloyd‐Jones, Hongyan Ning, Norrina Allen, Morgana Mongraw‐Chaffin, Kelley Pettee Gabriel, Vanessa Xanthakis, Arnita F. Norwood, et al.

    Background: Cardiovascular disease is a risk factor for severe COVID‐19 (ie, hospitalization or death). Whether better cardiovascular health (CVH) is associated with lower risk of severe COVID‐19 among adults without cardiovascular disease is unknown. We aimed to test if the American Heart Association's Life's Essential 8 (LE8) metric and its components were associated with severe COVID‐19 in the C4R (Collaborative Cohort of Cohorts for COVID‐19 Research) consortium. Methods: Participants with cardiovascular disease were excluded. Two waves of questionnaires, events surveillance, and a serosurvey identified COVID‐19 infections. Associations of incident severe COVID‐19 with continuous LE8, categorical LE8 (low [<50], moderate [50 to <80], and high [≥80] CVH), and individual LE8 components, were tested in adjusted cause‐specific hazards models. Results: Among 29 740 participants in 9 cohorts (mean age, 66±14 years; 61% women; 35% White race; 22% Black race; 34% Hispanic ethnicity), there were 681 severe COVID‐19 cases between March 1, 2020, and February 28, 2023. There was a 20% lower hazard of severe COVID‐19 per each 1‐SD higher LE8 (adjusted hazard ratio [aHR], 0.80 [95% CI, 0.73–0.88]). Relative to low CVH, high CVH was associated with lower risk of severe COVID‐19 (aHR, 0.54 [95% CI, 0.37–0.78]); this was not seen for moderate CVH (aHR, 0.81 [95% CI, 0.64–1.04]). Of LE8 components, better physical activity, body mass index, blood pressure, and sleep were associated with a lower hazard of severe COVID‐19. Conclusions: Better CVH was associated with lower severe COVID‐19 risk among cardiovascular disease–free adults. Whether CVH optimization could mitigate adverse risk from COVID‐19 and other harmful viruses warrants further investigation.


  • Open Access

    CT-adipose measures identify severe SARS-CoV-2 risk beyond traditional obesity metrics: a C4R cohort study

    by Nadine Al-Naamani, Pallavi Balte, Michael G. S. Shashaty, Asma Sharaf, James G. Terry, John Jeffrey Carr, Matthew Allison, Cheryl A. M. Anderson, Surya P. Bhatt, Michelle T. Long, et al.

    Higher body mass index (BMI) increases risk of respiratory failure and death from SARS-CoV-2 infection. BMI is imprecise and fails to account for adipose t

  • Pipe and cigar use, lung function decline and clinical outcomes: an analysis of the NHLBI Pooled Cohorts Study

    by William M Gardner, Pallavi P Balte, Christina M Eckhardt, Jack E Morris, Surya P Bhatt, David J Couper, Neal D Freedman, David R Jacobs, Ravi Kalhan, Laura R Loehr, et al.

    Introduction: Smoked tobacco is a leading risk factor for cardiopulmonary disease. Pipe and cigar use remains common among US adults, yet its risks remain insufficiently understood. Methods: We analysed data from five pooled cohorts with adults enrolled from 1971 to 2011 with follow-up through 2018. Pipe/cigar use was defined by baseline self-report. Forced expiratory volume in 1 s (FEV 1 ), forced vital capacity (FVC) and FEV 1 /FVC ratio were measured by spirometry. All-cause mortality, coronary heart disease mortality and hospitalisation, respiratory-related mortality, and chronic obstructive pulmonary disease (COPD) mortality and hospitalisation were classified via adjudication or validated algorithms. Associations were estimated with linear mixed models and Fine-Gray subdistribution hazards models adjusted for sociodemographic and clinical factors. Results: Among 22 823 participants (mean (SD) age 48.0 (15.7) years; 44.9% male sex; 70.5% white, 25.4% black, 2.4% Hispanic/Latino), 2621 (11.5%) reported ever pipe/cigar use, including 518 (2.3%) exclusive users without cigarette history. Compared with never tobacco users (n=9931), exclusive pipe/cigar use was associated with faster decline in FEV 1 (3.36 mL/year; 95% CI 1.99 to 4.72), FVC (3.73 mL/year; 95% CI 2.05 to 5.42) and FEV 1 /FVC (0.031 per year; 95% CI 0.008 to 0.054). Exclusive users had higher all-cause mortality (adjusted HR (aHR) 1.24; 95% CI 1.08 to 1.41), COPD hospitalisation/mortality (aHR 2.02; 95% CI 1.41 to 2.90) and preserved ratio impaired spirometry (aHR 1.83; 95% CI 1.24 to 2.71). Conclusion: Pipe and cigar use was associated with accelerated lung function decline and increased mortality and cardiopulmonary events, including among never cigarette users. These findings underscore the need for prevention and cessation efforts targeting non-cigarette tobacco.

  • Open Access

    Quantifying the impact of early life growth adversity on later life health

    by Raphael Goldman-Pham, Matthew P. Alter, Rebecca Bao, Sophie É. Collins, Catherine L. Debban, James P. Allinson, Antony Ambler, Alain G. Bertoni, Avshalom Caspi, Stephanie Lovinsky-Desir, et al.

    Background: Early-life growth adversity is important to later-life health, but precision assessment in adulthood is challenging. We evaluated whether the difference between attained and genotype-predicted adult height (“height-GaP”) would associate with prospectively ascertained early-life growth adversity and later-life all-cause and cardiovascular mortality. Methods: Data were first analyzed from the Avon Longitudinal Study of Parents and Children (ALSPAC; n = 4582; 56/43% female/male) and UKBiobank ( n = 483,385; 54/46% female/male). Genotype-predicted height was calculated using a multi-ancestry polygenic height score. Height-GaP was calculated as the difference between measured and genotype-predicted adult height. Early-life growth conditions were ascertained prospectively via standardized procedures (ALSPAC) and mortality via death register (UKBiobank). Regression models examined: (i) adult height-GaP as the outcome with early-life growth conditions as predictors; and (ii) mortality as the outcome with adult height-GaP as predictor. All models were adjusted for age, sex, genotype-predicted height and genetic ancestry. Analyses were replicated in the Dunedin Multidisciplinary Health and Development Study (DMHDS; n = 855; 49/51% female/male) and the Multi-Ethnic Study of Atherosclerosis (MESA; n = 6352; 52/48% female/male). Results: Here we show that among ALSPAC participants (median [IQR] age: 24 [18-25] years at height-GaP assessment), lower gestational age at birth, greater pre- and post-natal deprivation indices, tobacco smoke exposure and less breastfeeding are associated with larger adult height-GaP deficit ( p < 0.01). Among UKBiobank participants (mean ± SD age: 56 ± 8 years at height-GaP assessment), height-GaP deficit is associated with death from all-causes (adjusted hazard ratio comparing highest-to-lowest height-GaP deficit quartile [aHR]: 1.25 95%CI: 1.21–1.29), atherosclerotic cardiovascular disease (aHR: 1.32 95%CI: 1.23–1.42) and coronary heart disease (aHR: 1.64 95%CI: 1.49-1.81). Early- and later-life height-GaP associations replicate in DMHDS and MESA. Conclusions: This study introduces a precision index of early-life growth adversity deployable in adulthood to investigate the developmental origins of longevity and improve health equity across the life course.


  • Prevalence and Prognostic Significance of COPD in Adults Younger than 50 Years of Age

    by Alejandro A. Diaz, Pallavi P. Balte, MeiLan Han, Ravi Kalhan, Surya P. Bhatt, David J. Couper, David R. Jacobs, Martha L. Daviglus, Laura R. Loehr, Stephanie J. London, et al.

    Identification of chronic obstructive pulmonary disease (COPD) diagnosed before 50 years of age ("young COPD") will help enable the study of preventive and therapeutic interventions for classically diagnosed COPD in later life. However, there remains uncertainty about the definition of young COPD and its prognostic significance. We assessed the prevalence of young COPD, defined here as spirometric airflow obstruction plus symptoms of cough, phlegm, and dyspnea or 10 or more pack-years of smoking, among 18-to-49-year-old participants from four pooled, prospective U.S. cohorts. We evaluated the association of young COPD with premature mortality and respiratory and cardiovascular events over follow-up, using multivariable-adjusted proportional hazards models. Among 10,680 participants (median age, 40 years; 56.8% women; 41.7% Black; 51.1% unexposed to smoking), the prevalence of people meeting our case definition of young COPD was 4.5%. Compared with nonobstructed participants, the adjusted hazard ratio (an adjusted hazard ratio greater than unity indicates more incident cases) for participants with young COPD for death before 75 years of age was 1.43 (95% confidence interval [CI], 1.19 to 1.73; P<0.001); for incident hospitalization or death due to chronic lower respiratory disease, the adjusted hazard ratio was 2.56 (95% CI, 2.05 to 3.20); for coronary heart disease, the adjusted hazard ratio was 1.12 (95% CI, 0.85 to 1.47); and for heart failure, the adjusted hazard ratio was 1.72 (95%CI, 1.26 to 2.35). The hazards of the clinical outcomes in participants with simple obstruction (spirometric obstruction without symptoms and <10 pack-years; prevalence, 2.4%) were similar to those of nonobstructed participants. Young COPD was present in 4.5% of adults under 50 years of age in the cohorts examined. The diagnosis was associated with premature mortality as well as respiratory and heart-failure events. (Funded by the National Heart, Lung, and Blood Institute and others.).


  • Open Access

    Associations of Prepandemic Lung Function and Structure with COVID-19 Outcomes: The C4R Study

    by Pallavi P. Balte, John S. Kim, Yifei Sun, Nori Allen, Elsa Angelini, Alexander Arynchyn, R. Graham Barr, Michael Blaha, Russell Bowler, Jeff Carr, et al.

    Rationale: Increased risk of coronavirus disease (COVID-19) hospitalization and death has been reported among patients with clinical lung disease. Objectives: To test the association of objective measures of prepandemic lung function and structure with COVID-19 outcomes in U.S. adults. Methods: Prepandemic obstruction (FEV1/FVC < 0.70) and restriction (FEV1/FVC ⩾ 0.7, FVC < 80%) were defined based on the most recent spirometry exam conducted in 11 prospective U.S. general population–based cohorts. Severe obstruction was classified by FEV1 < 50%. Percentage emphysema, percentage high-attenuation areas, and interstitial lung abnormalities were defined on computed tomography in a subset. Incident COVID-19 was ascertained via questionnaires, serosurvey, and medical records from 2020 to 2023 and classified as severe (hospitalized or fatal) or nonsevere. Cause-specific hazard models were adjusted for sociodemographics, anthropometry, smoking, comorbidities, and COVID-19 vaccination status. Measurements and Main Results: Among 29,323 participants (mean age, 67 yr), there were 748 severe incident COVID-19 cases over median follow-up of 17.3 months from March 1, 2020. Greater hazards of severe COVID-19 were associated with severe obstruction (vs. normal; adjusted hazard ratio [aHR], 2.11; 95% confidence interval [CI], 1.02–1.27), restriction (vs. normal; aHR, 1.40; 95% CI, 1.12–1.76), and percentage emphysema (highest vs. lowest quartile; aHR, 1.64; 95% CI, 1.03–2.61), but not greater high-attenuation areas or interstitial lung abnormalities. COVID-19 vaccination provided greater absolute risk reduction in these groups. Results were similar in participants without smoking, obesity, or clinical cardiopulmonary disease. Conclusions: Prepandemic severe spirometric obstruction, spirometric restriction, and greater percentage emphysema lung on computed tomography were associated with risk of severe COVID-19. These findings support enhanced COVID-19 risk mitigation for individuals with impaired lung health and warrant further mechanistic studies on interactions of lung function, structure, and vulnerability to acute respiratory illnesses.


  • Open Access

    COVID-19 and Cognitive Change in a Community-Based Cohort

    by Ryan T. Demmer, Talea Cornelius, Zarina Kraal, James R. Pike, Yifei Sun, Pallavi Balte, Chaoqi Wu, Norrina B. Allen, Mary Cushman, Astrid M. Suchy-Dicey, et al.

    Importance: SARS-CoV-2 infection has been linked to neurotoxic effects and cognitive deficits.Objective: To determine whether decreases in cognitive function were accelerated after SARS-CoV-2 infection compared with individuals not infected.Design, Setting, and Participants: Multicenter, prospective cohort study from 2016 to 2022 among 3525 participants alive on March 1, 2020, and enrolled in The Atherosclerosis Risk in Communities (ARIC) study and the Collaborative Cohort of Cohorts for COVID-19 Research study who completed a prepandemic cognitive assessment and a pandemic-era assessment of SARS-CoV-2 infection. Final analyses performed in November 2024.Exposure: SARS-CoV-2 infection determined via self-report of a positive SARS-CoV-2 test or health care professional diagnosis of COVID-19, a positive SARS-CoV-2 antinucleocapsid antibody response, or presence of an administrative code for COVID-19 on medical records.Main outcomes and measures: A neuropsychological battery assessed multiple cognitive domains, and a cocalibrated confirmatory factor analysis generated factor scores for global cognitive function. The primary outcome was the rate of excess change in cognitive function.Results: The 3525 eligible participants had a mean (SD) age of 80.8 (4.7) years, 2085 (59.1%) were female, 752 (21.4%) were Black, and 2773 (78.6%) were White. SARS-CoV-2 infection was detected among 307 participants (8.7%), 103 of whom (33.6%) were hospitalized. Among uninfected participants, the mean annualized change in cognitive function was −0.09 (95% CI, −0.13 to −0.04). Compared with this rate, change was faster (β = −0.06; 95% CI, −0.09 to −0.02) among participants hospitalized for infection, but not different from participants who were infected but not hospitalized (β = 0.00; 95% CI, −0.02 to 0.03). The association among participants hospitalized for infection was evident in the cognitive domains of memory and executive function, but not language.Conclusions and relevance: This cohort study of older participants found accelerated decreases in cognition among individuals hospitalized for SARS-CoV-2 infection, but not nonhospitalized infection, in comparison with individuals not yet infected.